Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma

Masahiro Chiba, Joji Shimono, Keito Suto, Takashi Ishio, Tomoyuki Endo, Hideki Goto, Hiroo Hasegawa, Michiyuki Maeda, Takanori Teshima, Yibin Yang, Masao Nakagawa

Blood (2024) 143 (14): 1379–1390.

https://doi.org/10.1182/blood.2023021423

Published: 2024

Includes: Supplemental data

Journal Articles

Genome-Wide CRISPR Screen Identifies ZNF451 Regulating Sensitivity to Topoisomerase 2 Inhibitors in Peripheral T-Cell Lymphoma Cells

Keito Suto, Masahiro Chiba, Takashi Ishio, Hideki Goto, Tomoyuki Endo, Michiyuki Maeda, Takanori Teshima, Masao Nakagawa

Blood (2023) 142 (Supplement 1): 4182.

https://doi.org/10.1182/blood-2023-180529

Published: 2023

Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 602.

https://doi.org/10.1182/blood-2023-179474

Published: 2023

Journal Articles

Addition of High-Dose Methotrexate to Initial Chemotherapy Improved Treatment Outcome of Patients with Newly Diagnosed Intravascular Large B-Cell Lymphoma: A Multicenter, Retrospective Study

Blood (2023) 142 (Supplement 1): 440.

https://doi.org/10.1182/blood-2023-181183

Published: 2023

Journal Articles

Genome-Wide CRISPR Screen Identifies MAD2L1BP, ANAPC15 and SLC39A7 As Intrinsic Regulators for Brentuximab Vedotin Sensitivity in Peripheral T-Cell Lymphoma Cells

Keito Suto, Masahiro Chiba, Takashi Ishio, Hideki Goto, Tomoyuki Endo, Michiyuki Maeda, Takanori Teshima, Masao Nakagawa

Blood (2023) 142 (Supplement 1): 51.

https://doi.org/10.1182/blood-2023-180348

Published: 2023

Journal Articles

Low-Dose ATG Has the Same Risk of CMV Reactivation after Allogeneic PBSCT As Ptcy, but Letemovir Is Effective in Preventing CMV Reactivation

Takahide Ara, Yuta Hasegawa, Hiroyuki Ohigashi, Toshihiro Matsukawa, Souichi Shiratori, Atsushi Yasumoto, Hideki Goto, Masahiro Onozawa, Masao Nakagawa, Kaoru Kahata, Tomoyuki Endo, Daigo Hashimoto, Takanori Teshima

Blood (2023) 142 (Supplement 1): 3546.

https://doi.org/10.1182/blood-2023-191306

Published: 2023

Journal Articles

Baseline 18 f-Fluorodeoxyglucose PET/CT Radiomics Predicts Outcome in Newly Diagnosed Intravascular Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 6321.

https://doi.org/10.1182/blood-2023-188507

Published: 2023

Journal Articles

Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT

Blood (2023) 142 (5): 477–492.

https://doi.org/10.1182/blood.2023019875

Published: 2023

Includes: Supplemental data

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 790–791.

https://doi.org/10.1182/blood-2022-169519

Published: 2022

Journal Articles

Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 6713–6714.

https://doi.org/10.1182/blood-2022-169208

Published: 2022

Journal Articles

Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas

Masahiro Chiba, Joji Shimono, Takashi Ishio, Norio Takei, Kohei Kasahara, Reiki Ogasawara, Takahide Ara, Hideki Goto, Koh Izumiyama, Satoko Otsuguro, Liyanage P. Perera, Hiroo Hasegawa, Michiyuki Maeda, Satoshi Hashino, Katsumi Maenaka, Takanori Teshima, Thomas A. Waldmann, Yibin Yang, Masao Nakagawa

Blood (2022) 140 (18): 1951–1963.

https://doi.org/10.1182/blood.2022015646

Published: 2022

Includes: Supplemental data

Journal Articles

Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma

Blood (2022) 139 (10): 1541–1556.

https://doi.org/10.1182/blood.2021012734

Published: 2022

Includes: Supplemental data

Journal Articles

Letermovir Is Effective for Prevention of Cytomegalovirus Reactivation in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Takahide Ara, Yuta Hasegawa, Hiroyuki Ohigashi, Souichi Shiratori, Atsushi Yasumoto, Hideki Goto, Junichi Sugita, Masahiro Onozawa, Masao Nakagawa, Kaoru Kahata, Daigo Hashimoto, Takanori Teshima

Blood (2021) 138 (Supplement 1): 2858.

https://doi.org/10.1182/blood-2021-152116

Published: 2021

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

Feasibility and Kinetics of CD34+ Hematopoietic Cells Mobilization By Low-Dose Pegfilgrastim in Lymphoma Patients

Hideki Goto, MDPhD, Daisuke Hidaka, MD, Satoshi Yamamoto, MD PhD, Koji Hayasaka, Rie Michimata, Ikuko Kagawa, Kana Sunagoya, Hiroaki Iijima, Eiko Hayase, MD, Souichi Shiratori, MD PhD, Kohei Okada, MD PhD, Junichi Sugita, MD PhD, Masahiro Onozawa, MD PhD, Daigo Hashimoto, MD PhD, Kaoru Kahata, MD PhD, Katsuya Fujimoto, MD PhD, Tomoyuki Endo, MD PhD, Chikara Shimizu, MD PhD, Takanori Teshima, MD PhD

Blood (2017) 130 (Supplement 1): 4478.

https://doi.org/10.1182/blood.V130.Suppl_1.4478.4478

Published: 2017

Journal Articles

PTK7 Is Involved in the Chemotherapy Resistance of T-Cell Acute Lymphoblastic Leukemia through Interaction with FADD-Death Domain

Hideki Goto, MD PhD, Rachel Wilkie Grantham, PhD, Motoaki Mizuuchi, Tetsuji Yamaguchi, Takanori Teshima, MD PhD, John C. Reed, MD PhD, Shu-ichi Matsuzawa, PhD

Blood (2015) 126 (23): 3701.

https://doi.org/10.1182/blood.V126.23.3701.3701

Published: 2015

Journal Articles

Chemical Biology Strategy Reveals Cell Lineage- and Cell Differentiation-Specific Small Molecule Inhibitors of NF-κB.

Hideki Goto, MD, PhD, Paul Diaz, PhD, Shu-ichi Matsuzawa, PhD, Eduard Sergienko, PhD, Steve Vasile, PhD, Thomas Chung, PhD, Carina Wimer, Michael Hedrick, PhD, Ricardo Correa, PhD, Thomas J Kipps, MD, PhD, Anthony Pinkerton, PhD, John C. Reed, MD, PhD

Blood (2012) 120 (21): 2421.

https://doi.org/10.1182/blood.V120.21.2421.2421

Published: 2012

Journal Articles

Both DOCK180 and DOCK2 Participate in the CXCL12 and CCL19 Dependent Chemotaxis of Human Dendritic Cells Derived From Monocytes Through the Activation of Rac

Hideki Goto, MD, PhD, Mitsufumi Nishio, MD, PhD, Katsuya Fujimoto, MD, PhD, Tomoyuki Endo, MD, PhD, Masato Obara, MD, PhD, Keisuke Yamaguchi, MD, PhD, Yukari Takeda, MD, PhD, Hiroshi Nishihara, MD, PhD, Takao Koike, MD, PhD, Masahiro Imamura, MD, PhD

Blood (2011) 118 (21): 521.

https://doi.org/10.1182/blood.V118.21.521.521

Published: 2011

Journal Articles

FCGR3A-158V/F Polymorphism May Correlate with the Levels of Immunoglobulin in Patients with Non-Hodgkin’s Lymphoma after Rituximab Treatment as An Adjuvant to Autologous Stem Cell Transplantation.

Mitsufumi Nishio, MD, PhD, Tomoyuki Endo, M.D., Ph.D., Katsuya Fujimoto, M.D., Ph.D., Satoshi Yamamoto, M.D., Ph.D., Masato Obara, M.D., Keisuke Yamaguchi, M.D., Yukari Takeda, M.D., Hideki Goto, M.D., Ikumi Kasahara, M.D., Norihiro Sato, M.D., Ph.D., Takao Koike, M.D., Ph.D.

Blood (2008) 112 (11): 3245.

https://doi.org/10.1182/blood.V112.11.3245.3245

Published: 2008

NARROW

Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma

Genome-Wide CRISPR Screen Identifies ZNF451 Regulating Sensitivity to Topoisomerase 2 Inhibitors in Peripheral T-Cell Lymphoma Cells

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Addition of High-Dose Methotrexate to Initial Chemotherapy Improved Treatment Outcome of Patients with Newly Diagnosed Intravascular Large B-Cell Lymphoma: A Multicenter, Retrospective Study

Genome-Wide CRISPR Screen Identifies MAD2L1BP, ANAPC15 and SLC39A7 As Intrinsic Regulators for Brentuximab Vedotin Sensitivity in Peripheral T-Cell Lymphoma Cells

Low-Dose ATG Has the Same Risk of CMV Reactivation after Allogeneic PBSCT As Ptcy, but Letemovir Is Effective in Preventing CMV Reactivation

Baseline 18 f-Fluorodeoxyglucose PET/CT Radiomics Predicts Outcome in Newly Diagnosed Intravascular Large B-Cell Lymphoma

Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma

Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma

Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas

Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma

Letermovir Is Effective for Prevention of Cytomegalovirus Reactivation in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Feasibility and Kinetics of CD34+ Hematopoietic Cells Mobilization By Low-Dose Pegfilgrastim in Lymphoma Patients

PTK7 Is Involved in the Chemotherapy Resistance of T-Cell Acute Lymphoblastic Leukemia through Interaction with FADD-Death Domain

Chemical Biology Strategy Reveals Cell Lineage- and Cell Differentiation-Specific Small Molecule Inhibitors of NF-κB.

Both DOCK180 and DOCK2 Participate in the CXCL12 and CCL19 Dependent Chemotaxis of Human Dendritic Cells Derived From Monocytes Through the Activation of Rac

FCGR3A-158V/F Polymorphism May Correlate with the Levels of Immunoglobulin in Patients with Non-Hodgkin’s Lymphoma after Rituximab Treatment as An Adjuvant to Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only